利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

93 条记录 (耗时 0.035 秒)

    Treating obesity with muscarinic receptor M1 antagonists
    21.
    发明授权
    Treating obesity with muscarinic receptor M1 antagonists 失效
    用毒蕈碱受体M1拮抗剂治疗肥胖

    公开(公告)号：US08748419B2

    公开(公告)日：2014-06-10

    申请号：US11763313

    申请日：2007-06-14

    申请人： Brian Seed ,  Jordan Mechanic

    发明人： Brian Seed ,  Jordan Mechanic

    IPC分类号： C07D487/04 ,  A61K31/55 ,  C07D333/20 ,  C07D307/80 ,  A61K31/135

    CPC分类号： A61K31/343 ,  A61K31/135 ,  A61K31/137 ,  A61K31/381 ,  A61K31/55 ,  A61K31/551 ,  A61K31/5513 ,  A61K45/06 ,  A61K2300/00

    摘要： Provided are methods of treating obesity and effecting desired weight loss or preventing undesired weight gain by administration of a preferential muscarinic acetylcholine receptor M1 antagonist, optionally with at least one antidepressant other than a selective muscarinic acetylcholine receptor M1 antagonist. The preferential muscarinic acetylcholine receptor M1 antagonist, optionally can be administered with an anti-obesity agent, for example, an anorexiant. The invention also provides for pharmaceutical compositions and kits for administration of at least one selective muscarinic acetylcholine receptor M1 antagonist in combination with at least one antidepressant other than a selective muscarinic acetylcholine receptor M1 antagonist.

    摘要翻译： 提供了通过施用优选的毒蕈碱性乙酰胆碱受体M1拮抗剂，任选地与选择性毒蕈碱性乙酰胆碱受体M1拮抗剂以外的至少一种抗抑郁药来治疗肥胖症并实现所需体重减轻或预防不希望的体重增加的方法。 优选的毒蕈碱性乙酰胆碱受体M1拮抗剂，任选地可以与抗肥胖剂，例如无痛剂一起施用。 本发明还提供用于至少一种选择性毒蕈碱性乙酰胆碱受体M1拮抗剂与除选择性毒蕈碱性乙酰胆碱受体M1拮抗剂之外的至少一种抗抑郁药组合的药物组合物和试剂盒。

    Methods and compositions for the rapid and enduring relief of inadequate myocardial function
    23.
    发明授权
    Methods and compositions for the rapid and enduring relief of inadequate myocardial function 有权

    公开(公告)号：US07109206B2

    公开(公告)日：2006-09-19

    申请号：US09735024

    申请日：2000-12-12

    申请人： Brian Seed ,  John C. Seed

    发明人： Brian Seed ,  John C. Seed

    IPC分类号： A61K31/505 ,  A61K31/44 ,  A61K31/40 ,  A61K31/35 ,  A61K31/21

    CPC分类号： A61K31/505 ,  A61K31/506 ,  A61K31/60 ,  A61K31/785 ,  Y10S514/824 ,  A61K2300/00

    摘要： Disclosed are methods and compositions for reducing coronary artery stenosis, restoring blood flow to infarcted myocardium, improving myocardial perfusion, reducing heart attacks or other adverse cardiovascular events, or treating symptoms of inadequate myocardial function in a mammal involving administering to the mammal (a) a compound that includes eicosapentaeneoic acid or docosahexaeneoic acid and (b) a cholesterol-lowering therapeutic, combined with dietary restrictions (resulting in aggressive loading of marine lipids), whereby a serum LDL concentration of less than 75 mg/dl (and preferably less than 55 mg/dl) is achieved. One particular method involves administering to the mammal a combination that includes (a) a compound that includes an eicosapentaeneoic or docosahexaeneoic acid (for example, a marine lipid) and (b) a cholesterol synthesis or transfer inhibitor, and which may also optionally include aspirin and/or niacin. The methods and compositions of the invention may also further include a bile acid sequestrant and/or buspirone. Also disclosed are methods for treating heart disease that involve administration of buspirone.

    Cloned genes encoding IG-CD4 fusion proteins and the use thereof
    26.
    发明授权
    Cloned genes encoding IG-CD4 fusion proteins and the use thereof 失效
    编码IG-CD4融合蛋白的克隆基因及其用途

    公开(公告)号：US6117656A

    公开(公告)日：2000-09-12

    申请号：US479353

    申请日：1995-06-07

    申请人： Brian Seed

    发明人： Brian Seed

    IPC分类号： C07K14/73 ,  C07K16/00 ,  C07K19/00 ,  C12N15/62

    CPC分类号： C07K16/00 ,  C07K14/70514 ,  C07K2319/00 ,  C07K2319/036 ,  C07K2319/30 ,  C07K2319/32 ,  C07K2319/33

    摘要： The invention relates to a fusion protein which comprises an immunoglobulin of the IgM, IgG1 or IgG3 immunoglobulin class, wherein the variable region of the light or heavy chain has been replaced with CD4 or fragment thereof which is capable of binding to gp120. The invention also relates to an immunoglobulin-like molecule comprising the fusion protein of the invention together with an immunoglobulin light or heavy chain. The invention also relates to a method of treating HIV or SIV infection comprising administering the fusion proteins or immunoglobulin-like molecules of the invention to an animal. The invention also relates to assays for HIV or SIV comprising contacting a sample suspected of containing HIV or SIV gp120 with the immunoglobulin-like molecule of fusion protein of the invention, and detecting whether a complex is formed.

    摘要翻译： 本发明涉及包含IgM，IgG1或IgG3免疫球蛋白类免疫球蛋白的融合蛋白，其中轻链或重链的可变区已经被能够结合gp120的CD4或其片段替代。 本发明还涉及包含本发明的融合蛋白和免疫球蛋白轻链或重链的免疫球蛋白样分子。 本发明还涉及一种治疗HIV或SIV感染的方法，其包括向动物施用本发明的融合蛋白或免疫球蛋白样分子。 本发明还涉及用于HIV或SIV的测定法，其包括将怀疑含有HIV或SIV gp120的样品与本发明的融合蛋白的免疫球蛋白样分子接触，并检测是否形成复合物。

    THERAPEUTIC USES OF SGLT2 INHIBITORS
    30.
    发明申请
    THERAPEUTIC USES OF SGLT2 INHIBITORS 审中-公开
    SGLT2抑制剂的治疗用途

    公开(公告)号：US20110077212A1

    公开(公告)日：2011-03-31

    申请号：US12888326

    申请日：2010-09-22

    申请人： Brian Seed ,  Jordan Mechanic

    发明人： Brian Seed ,  Jordan Mechanic

    IPC分类号： A61K31/70 ,  A61P7/10 ,  A61P3/10

    CPC分类号： A61K31/00 ,  A61K31/70 ,  A61K45/06 ,  A61K2300/00

    摘要： Provided are methods of using one or more SGLT2 inhibitors, independently or in combination, for treating edema or reducing fluid retention. The invention also provides methods of using one or more SGLT2 inhibitors for the preparation of a medicament for treating edema or fluid retention. Methods are also provided for treating diabetes with an amount of one or more SGLT2 inhibitors and one or more PPAR-gamma agonists.

    摘要翻译： 提供了独立地或组合地使用一种或多种SGLT2抑制剂来治疗水肿或减少流体保留的方法。 本发明还提供使用一种或多种SGLT2抑制剂制备用于治疗水肿或液体保留的药物的方法。 还提供了用一种或多种SGLT2抑制剂和一种或多种PPAR-γ激动剂治疗糖尿病的方法。